Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: This study evaluates the interaction of donor and recipient age with outcomes following heart transplantation under the 2018 heart allocation system.

Methods: The United Network for Organ Sharing registry was queried to analyze adult primary isolated orthotopic heart transplant recipients and associated donors from August 18, 2018, to June 30, 2021. Both recipient and donor cohorts were grouped according to age: <65 and ≥65 y for recipients and <50 and ≥50 y for donors. The primary outcome was survival. Subanalyses were performed to evaluate the impact of donor age.

Results: A total of 7601 recipients and 7601 donors were analyzed. Of these, 1584 recipients (20.8%) were ≥65 y old and 560 donors (7.4%) were ≥50 y old. Compared with recipients <65, recipients ≥65 had decreased 1-y (88.8% versus 92.3%) and 2-y (85.1% versus 88.5%) survival rates ( P  < 0.001). The association of recipient age ≥65 with lower survival persisted after adjusting for potential cofounders (hazard ratio, 1.38; 95% confidence interval, 1.18-1.61; P  < 0.001). Recipients <65 with donors ≥50 had comparable 1-y and 2-y survival rates to recipients <65 with donors <50 ( P  = 0.997). Conversely, transplantation of older allografts was associated with lower 1-y (84.2% versus 89.4%) and 2-y (79.5% versus 85.8%) survival rates in recipients ≥65 ( P  = 0.025).

Conclusions: Recipient age ≥65 continues to be associated with worse survival following heart transplantation in the 2018 heart allocation system compared with younger recipients. Donors ≥50 may be acceptable among recipients <65 with comparable outcomes. However, careful donor age selection should be considered for recipients ≥65, as the use of younger donor allografts appears to improve posttransplantation survival.

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0000000000005194DOI Listing

Publication Analysis

Top Keywords

donor recipient
8
recipient age
8
orthotopic heart
8
heart transplantation
8
transplantation 2018
8
2018 heart
8
heart allocation
8
heart
5
age influence
4
influence outcomes
4

Similar Publications

Nondisclosure of use of antiretroviral medications in Canadian blood donors.

Transfusion

September 2025

Medical Affairs and Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.

Introduction: Donors are deferred if they are on antiretroviral medications (ARV) as post-exposure or pre-exposure prophylaxis (PEP or PrEP) for human immunodeficiency virus (HIV). We assessed donor compliance by measuring ARV levels in selected anonymized donor samples collected from September 22, 2022 to December 31, 2024, almost all after the introduction of sexual risk behavior screening.

Methods: EDTA plasma samples collected at the time of donation (retention samples) were retrieved, frozen, and shipped for measurement of tenofovir and emtricitabine.

View Article and Find Full Text PDF

Research Objective: Among singleton live births resulting from donor oocyte cycles, do perinatal outcomes differ between single (SET) and double embryo transfers (DET)?

Methods: We utilized a retrospective cohort of 610 recipients who had a singleton livebirth following nonidentified vitrified donor oocyte IVF cycle from a fertility clinic in the southeast US, 2008-2016. Perinatal outcomes included gestational age and birth weight. Preterm birth was defined as <37 weeks and low birth weight was defined as <2500 grams.

View Article and Find Full Text PDF

Heart transplant candidates that are highly sensitized against human leukocyte antigens (HLA) face ongoing challenge in finding immunologically compatible donors. Desensitization strategies aimed at reducing HLA antibody titers have variable success rates. Imlifidase, a novel immunoglobulin G-degrading enzyme derived from Streptococcus pyogenes has been successfully used to eliminate pre-formed antibodies in sensitized kidney transplant recipients.

View Article and Find Full Text PDF

The use of donor eggs, sperm and embryos in medically assisted reproduction (MAR) provide new possibilities for reproductive assistance and family-making. In clinical practice, it also brings to light questions of responsibility and ethical conduct. Despite this, fertility practitioners' reasoning in clinical decision-making remains surprisingly understudied.

View Article and Find Full Text PDF